Eli Lilly’s Jaypirca (pirtobrutinib) is forecast to become the market leader in BTK inhibitors for CLL, garnering nearly 60% share with about $3 billion in sales by 2032, according to GlobalData.
Tag Archive for: pirtobrutinib
The FDA granted accelerated approval to Eli Lilly’s reversible BTK inhibitor Jaypirca (pirtobrutinib) for the treatment of chronic lymphocytic leukemia or small lymphocytic leukemia in adult patients who have undergone at least two prior lines of therapy, including another BTK inhibitor and a BCL-2 inhibitor.
The agency’s decision will help Lilly enter a sector, where drugs from rivals such as Abbvie, Pfizer, and Johnson & Johnson are already jostling for a share of the multi-billion dollar market.
Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.
